Pharmacotherapy for age-related behavioral deficiencies.
This review observes a distinction between drugs for treating age-related behavioral losses or impairments among the old and the psychopharmacotherapeutic drugs used in treating disturbed or disordered behavior in adults of various ages. The placebo-controlled studies confirm numerous responses to drugs designed specifically for treating impaired behavior in old people, and the responses of normal or mildly impaired subjects to some of these drugs suggest the possibility of prophylactic applications.
D000328:Adult; D000368:Aged; D000375:Aging; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D006801:Humans; D006931:Hyperbaric Oxygenation; D002504:Meclofenoxate / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use; D010208:Papaverine / Q000627:therapeutic use; D010889:Piracetam / Q000627:therapeutic use; D010919:Placebos; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D009539:Nicotinic Acids; D010919:Placebos; D011619:Psychotropic Drugs; D014665:Vasodilator Agents; D014815:Vitamins; D002504:Meclofenoxate; D010208:Papaverine; D010889:Piracetam